Navigation Links
WuXi PharmaTech Celebrates Dr. Joseph Vacca's Induction into American Chemical Society's Medicinal Chemistry Hall of Fame
Date:9/4/2012

SHANGHAI, Sept. 4, 2012 /PRNewswire/ -- Dr. Joseph Vacca, Senior Vice President of the Early Success Sharing Partnerships (ESSP) business unit of WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, was inducted into the Medicinal Chemistry Hall of Fame of the American Chemical Society (ACS), the world's largest scientific society with more than 164,000 members.  The induction was held in August 2012 during the 244th ACS National Meeting in Philadelphia.  Dr. Vacca was honored for his outstanding contributions to the discovery of novel therapeutics, including CRIXIVAN™, Isentress™, and many compounds in advanced clinical studies.

In the spirit of celebrating excellence, WuXi hosted a special luncheon to honor Dr. Vacca, attended by many colleagues, collaborators, and distinguished guests of WuXi's global network.  At the event, several leading chemists praised Dr. Vacca's accomplishments.

"Dr. Vacca sets the standard of leadership in the discipline of drug discovery," commented Dr. Paul Anderson, former Merck Chemistry Site Head, past ACS President, and winner of the ACS Priestley Medal.

"Advancing innovative science to effective therapies is an enormous challenge that requires strong partnership between academia and industry," added Dr. Chi-Huey Wong, the 2012 ACS Arthur C. Cope Award recipient, Ernest W. Hahn Professor of Chemistry at the Scripps Research Institute, and President of Academia Sinica.  "Expertise from veterans like Dr. Vacca will be vital to speed translation of discoveries into medicines for patients."

"We are particularly delighted that ACS has recognized Dr. Vacca's contributions to the chemical society and to industry through his leadership in the discovery of important, ground-breaking therapies," commented Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.  "Today more than ever, our industry needs a strong collaborative ecosystem to improve R&D productivity for the benefit of our patients.  Dr. Vacca exemplifies WuXi's mission of providing the very finest industry expertise across our open-access platforms to enable anyone and any company to discover and develop drugs more efficiently and cost-effectively."

Dr. Vacca has had a distinguished career in medicinal chemistry and drug discovery.  Prior to working at WuXi, Dr. Vacca held positions within the Merck Research Laboratories Chemistry organization as Vice President of Chemistry at the Kenilworth, New Jersey, site and as the Global Head of Structural Chemistry.  He retired from Merck in November 2011.  Dr. Vacca is the author of more than 100 publications and patents and has received many awards, including the Merck Directors Award given by the Merck Board of Directors (1998); the Pharmaceutical Research and Manufacturers of America Discoverers Award (1999); the Intellectual Property Owners' National Inventor of the Year Award (1997); the European Patent Office's European Inventor of the Year for non-European inventors (2007); the ACS Award for Creative Invention (1999); and designation as a Merck Research Laboratories Presidential Fellow (2008).

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States.  As an innovation-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the timeline and lowering the cost of drug and medical device R&D.  WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec.  For more information, please visit http://www.wuxiapptec.com or contact:

Aaron Shi
Assistant Director of Corporate Communications
Tel: +86-21-5046-4362
Email: Aaron_Shi@wuxiapptec.com

Ronald Aldridge
Director of Investor Relations
Tel: +1-201-585-2048
Email: Ron_Aldridge@wuxiapptec.com

 


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
2. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
3. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
4. WuXi PharmaTech Announces Second-Quarter 2012 Results
5. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
6. WuXi PharmaTech Announces First-Quarter 2012 Results
7. Industry Leading Pharmaceutical News Website in-Pharmatechnologist.com Refocused and Relaunched
8. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
9. Cardinal Health Celebrates Community Pharmacists Commitment to Patient Care at Annual Trade Show for Independent Pharmacies
10. Collagen Matrix Celebrates 15th Anniversary in the Medical Device Business
11. Leading Pension Annuity Provider Legal & General, Celebrates 175 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
Breaking Medicine Technology:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):